



# Spermosens announces outcome of exercise of warrants series TO 5

**Spermosens AB (publ) ("Spermosens" or the "Company") today announces the outcome of the exercise of warrants of series TO 5 (the "Warrants"). A total of 467,740,274 shares were subscribed for through the exercise of Warrants, corresponding to an exercise rate of 100 percent. Spermosens will receive proceeds of approximately SEK 2.6 million before transaction costs.**

The total number of outstanding Warrants amounted to 467,740,274. One (1) Warrant entitled the holder to subscribe for one (1) new share in Spermosens at a subscription price of SEK 0.0055. The exercise period ran from 2 June 2025 to 16 June 2025. The outcome shows that the exercise rate amounted to 100 percent, corresponding to 467,740,274 Warrants exercised for the subscription of 467,740,274 shares. The exercised Warrants will be replaced by interim shares pending registration with the Swedish Companies Registration Office (sw. Bolagsverket).

As a result of the exercise of Warrants, the total number of shares will increase by 467,740,274, from 2,705,283,791 to 3,173,024,065, and the share capital will increase by SEK 935,480.548 from SEK 5,410,567.582 to SEK 6,346,048.130. This corresponds to a dilution of approximately 14.7 percent of the total number of shares and votes in the Company following registration of the new shares with the Swedish Companies Registration Office.

**Tore Duvold, CEO of Spermosens, comments:** *"We are very pleased with the full subscription of TO5. Together with the strategic investment completed in March, the proceeds will help us further accelerate the development of JUNO-Checked and support our business development efforts aimed at establishing license agreements with key players in the assisted reproductive technology (ART) market. This continued support strengthens our ability to realize the potential of our technology and bring it closer to patients in need of better IVF treatment."*

## Advisors

Eminova Partners Corporate Finance AB acted as financial advisor and Fram Advokatbyrå KB acted as legal advisor in connection with the exercise of the Warrants. Eminova Fondkommission AB acted as issue agent.

**For more information, please contact:**

Tore Duvold, CEO  
[info@spermosens.com](mailto:info@spermosens.com)

**Spermosens AB** is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see [www.spermosens.com](http://www.spermosens.com)